How does cosentyx compare in cost?

Cosentyx costs more than most competing psoriasis and arthritis drugs. The list price for a 150 mg dose in the U.S. stands at roughly $7,000 per month without insurance.

How much does insurance actually cover?
Many commercial plans place Cosentyx on specialty tiers that require prior authorization and copay assistance programs. Patients with high-deductible plans may still pay several thousand dollars out-of-pocket before assistance kicks in.

What savings programs exist?
Novartis offers a Copay Card that can reduce the monthly cost to as little as $0 for eligible commercially insured patients. Medicare and Medicaid recipients are not eligible for this program.

How does Cosentyx compare with Humira?
Humira’s average cash price is lower at about $5,500 per month, yet its biosimilars now sell for $1,000–$2,500 per month. Cosentyx has no biosimilar competition yet, so its price has stayed stable.

When will Cosentyx face biosimilar competition?
U.S. patents covering the drug expire between 2026 and 2030. The first biosimilar applications have already been filed, though litigation may delay launches until at least 2027.

Are there cheaper IL-17 inhibitors available?
Taltz and Siliq are priced in the same $5,500–$7,000 range. Taltz carries a similar copay card, while Siliq’s access is limited by a required REMS safety program.

Which drug offers the lowest net cost after rebates?
Payers report that negotiated net prices for Cosentyx and Taltz are now close, with some plans favoring Taltz because of deeper rebates. Actual patient cost depends on formulary placement and assistance eligibility.

[1] DrugPatentWatch.com
[2] Novartis patient support resources